Macrophage Activation by a Lipophilic Derivative of Muramyldipeptide within Nanocapsules: Investigation of the Mechanism of Drug Delivery
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cholesterol and Lipid Metabolism · Lipid Membrane Structure and Behavior · Neuropeptides and Animal Physiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (19)
Show source-provided references
1. Adam, A. & E. Lederer, 1984. Muramylpeptides: immunomodulators, sleep factors and vitamins. Med. Res. Rev. 4, 111–152.10.1002/med.2610040202 ↗
2. Ammoury, N., H. Fessi, J.P. Devissaguet, F. Puisieux & S. Benita, 1989. Physicochemical characterization of polymeric nanocapsules and in vitro release evaluation of indomethacin as a drug model. S.T.P. Pharma 5, 647–651.
3. Asano, T. & E.S. Kleinerman, 1993. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy. J. Immunother. 14, 286–292.10.1097/00002371-199311000-00006 ↗
4. Bijsterbosch, M.K., G.J. Ziere & T.J.C. Van Berkel, 1989. Lactosylated low density lipoprotein: a potential carrier for the site-specific of drugs to Küpffer cells. Mol. Pharmacol. 36, 484–486.10.1016/S0026-895X(25)09320-4 ↗
5. Devissaguet, J.P., H. Fessi & F. Puisieux, 1992. Process for the preparation of dispersible colloidal systems of a substance in the form of nanocapsules. U.S. Patent 140, 246.
6. Goldstein, J.L.,Y.K. Ho, S.K. Basu & M.S. Brown, 1979. Binding site on macrophages that mediates uptake and degradation of actetylated low density lipoprotein, producing massive cholesterol degradation. Proc. Natl. Acad. Sci. USA 76, 333–337.10.1073/pnas.76.1.333 ↗
7. Green, L.C., D.A. Warguer, J. Glowgoski, P.L. Skipper, J.S. Wishnok & J.R. Tannenbann, 1982. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal. Biochem. 126, 131–138.10.1016/0003-2697(82)90118-X ↗
8. Jorens, P.G., M. Rosseneu, A.-M. Devresse, H. Bult, B. Marescau & A.G. Herman, 1992. Diminished capacity to release metabolites of nitric oxide synthase in macrophages loaded with oxidized low-density lipoproteins. Eur. J. Pharmacol. 212, 113–115.10.1016/0014-2999(92)90082-F ↗
9. Merhi, G., A.W. Coleman, J.-Ph. Devissaguet & G.M. Barratt, 1996. Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives. J. Med. Chem. 39, 4483–4488.10.1021/jm960147u ↗
10. Morin, C., G. Barratt, H. Fessi, J.P. Devissaguet & F. Puisieux, 1994. Improved intracellular delivery of a muramyl dipeptide analog by means of nanocapsules, Int. J. Immunopharmac. 16, 451–456.10.1016/0192-0561(94)90035-3 ↗
11. Parant, M., F. Parant, L. Chedid, A. Yapo, J.F. Petit & E. Lederer, 1979.Fate of the synthetic immunoadjuvant muramyldipeptide (14C-labelled) in the mouse. Int. J. Immunopharmac. 1, 35–41.10.1016/0192-0561(79)90028-6 ↗
12. Phillips, N.C., M.L. Moras, L. Chedid, J.F. Petit, J.D. Tenu, E. Lederer, J.M. Bernard & P. Lefrancier, 1985. Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl dipeptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL). J. Biol. Resp. Mod. 4, 464–474.
13. Seyler, I., C. Morin, G. Barratt, M. Appel, J.P. Devissaguet & F. Puisieux, 1995. Induction of macrophage NO-synthase by an immunomodulator entrapped within polymeric nanocapsules. Eur. J. Pharm. Biopharm. 41, 49–54.
14. Shaw, J.M., W.S. Futch & L.B. Schook, 1988. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide. Proc. Natl. Acad. Sci. USA 85, 6112–6116.10.1073/pnas.85.16.6112 ↗
15. Stuehr, D.J. & C.F. Nathan, 1989. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169, 1543–1555.10.1084/jem.169.5.1543 ↗
16. Tenu, J.P., A. Adam, V. Souvannavong, A. Yapo, J.F. Petit & K. Douglas, 1989. Photoaffinity labelling of macrophages and B-lymphocytes using 125I-labelled aryl-azide derivatives of muramyldipeptide. Int. J. Immunopharmac. 11, 653–661.10.1016/0192-0561(89)90151-3 ↗
17. Van deWater, B., T.J.C. Van Berke & J. Kuiper, 1994. Activation of rat Küpffer cells to tumoricidal cells by the immunomodulator muramyl tripeptide-phosphatidylethanolamine incorporated into the novel drug carrier lactosylated low density lipoprotein. Mol. Pharmacol. 45, 971–977.10.1016/S0026-895X(25)10212-5 ↗
18. Yang, X., B. Cai, R.R. Sciacca & P.J. Cannon, 1994. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circulation Res. 74, 318–328.10.1161/01.RES.74.2.318 ↗
19. Yu,W.P., G.M. Barratt, J.P.Devissaguet & F. Puisieux, 1991. Antimetastatic activity in vivo of MDP-L-alanyl-cholesterol (MTPCHOL) entrapped in nanocapsules. Int. J. Immunopharmac. 13, 167–173.10.1016/0192-0561(91)90095-O ↗